College of Public Health, Zhengzhou University, No. 100 Kexue Avenue, Zhengzhou 450000, Henan, China.
Shiyan Centers for Disease Control and Prevention, China.
Anal Methods. 2024 Nov 14;16(44):7484-7493. doi: 10.1039/d4ay01253d.
Hepatitis C, one of the major infectious diseases posing a serious threat to human health, contributes a significant disease burden to global public health governance. Low diagnostic rates are a major barrier to eliminating hepatitis C in resource-constrained countries. As a result, the development of rapid, accurate, ultra-sensitive, and user-friendly POCT assays is desperately needed to improve the diagnostic rate and control of HCV. Here, we present a Visual One-Pot RT-RAA-Cas12a (HCV-VOpRCas12a) platform, which performed RT-RAA and CRISPR-based detection in a single tube by physical separation, and low-cost, readily accessible hand warmers were used as incubators. A visualization device was built to achieve the visual readout. The LoD of the HCV-VOpRCas12a platform was as low as 10 copies per μL and only took about 15 min to achieve HCV-RNA diagnosis. In the validation of 101 clinical serum samples, the detection sensitivity and specificity of the visualization device were 95% and 100%. The VOpRCas12a platform holds enormous potential in achieving a global strategy to eliminate the public threat of HCV infection by 2030 and in the next generation of real-time molecular diagnostics.
丙型肝炎是严重威胁人类健康的主要传染病之一,给全球公共卫生治理带来了巨大的疾病负担。在资源有限的国家,低诊断率是消除丙型肝炎的主要障碍。因此,迫切需要开发快速、准确、超灵敏和用户友好的 POCT 检测方法,以提高丙型肝炎的诊断率和控制水平。在这里,我们提出了一种可视化一步 RT-RAA-Cas12a(HCV-VOpRCas12a)平台,该平台通过物理分离在单个管中进行 RT-RAA 和基于 CRISPR 的检测,并使用低成本、易于获得的手暖器作为孵化器。我们构建了一个可视化设备来实现可视化读数。HCV-VOpRCas12a 平台的检测限低至每 μL 10 拷贝,仅需约 15 分钟即可完成 HCV-RNA 诊断。在对 101 份临床血清样本的验证中,可视化设备的检测灵敏度和特异性分别为 95%和 100%。VOpRCas12a 平台在实现到 2030 年消除丙型肝炎感染公共威胁的全球战略以及下一代实时分子诊断方面具有巨大潜力。